Y-90 spheres plus immunotherapy and targeted therapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have liver cancer (hepatocellular carcinoma) that is only in one side of your liver and has not spread outside the liver.
- Your cancer cannot be surgically removed right now, but your doctor thinks it might be possible after this treatment.
- Your liver function is good (Child-Pugh A) and your performance status is 0 or 1 (you are up and active most of the day).
- You have not had prior radiation, targeted therapy, immunotherapy, or liver artery treatments for your cancer.
- If you have hepatitis B or C, it must be controlled with antiviral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This study tests whether a targeted radiation treatment called Y-90 segmentectomy can shrink liver tumors. It is for people with one to three small liver tumors that cannot be removed by surgery or destroyed by heat or cold (ablation).
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.